Insufficient market incentives and rapid antibiotic resistance leave us vulnerable to the most deadly bacteria. Yet in the midst of this antibiotic crisis, another door is opening. Phare Bio launched in 2020 with an ambitious social venture model and the latest advances in machine learning to address this critical need. Phare addresses the “valley of death” -- the stage in preclinical development when most drugs fail -- with donor funding, and takes on more costly clinical development with strategic commercial partnerships and company spin-outs. This model enables Phare to develop a novel pipeline of AI-optimized antibiotic candidates, derisk these candidates through preclinical development, and build a sustainable clinical path to ensure that these therapies reach the patients in greatest need.
Phare streamlines and optimizes the development process by integrating world-class expertise and decades of experience in artificial intelligence (AI), bioengineering, and pharmaceutical development to rapidly discover and develop novel classes of antibiotics that target urgent threats like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. This unique and self-sustaining approach will enable us to outpace the emergence and global dissemination of antibiotic resistance.